Drug
Aaa617
Aaa617: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAA617 NCT06004661 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Latest
No recent events.
Follow Aaa617 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.